Wilson Sonsini Goodrich & Rosati advised LuxWall on IP and patent strategy for the transaction. LuxWall, a leader in glass-based transparent insulation solutions to reduce energy...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cytovale on intellectual property strategy generally and advised the company on IP matters related to the transaction. Cytovale, a commercial-stage...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Neo Medical on U.S. aspects of the financing. Neo Medical SA (Neo), a Swiss technology company specializing in spine surgery,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction. Halia Therapeutics announced it raised $30 million in Series C financing round led by Todd Pedersen, with continued...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Khosla Ventures on the transaction. Vivodyne announced the close of $38 million in total seed financing, led by Khosla Ventures, with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati provided IP and corporate counsel to DermBiont in the transaction. DermBiont announced its $35.2 million Series B financing. The financing was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aspect Biosystems on the transaction. Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, and leading global...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
